Skip to main content
SpringerLink
Log in

TBC 11251

IPI 1040

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-Aselective antagonist. J Med Chem 1997 May 23; 40: 1690–7

    Article  PubMed  CAS  Google Scholar 

  2. Texas biotechnology completes phase I safety trial for oral endothelin antagonist. PR Newswire [online].: Available from: URL: http://www.newspage.com [Accessed 1997 Dec 12]

  3. Texas Biotechnology Corporation. Texas Biotechnology presents clinical results on its endothelin A receptor antagonist, TBC11251, at AHA sessions [media release]. 1998 Nov 10

    Google Scholar 

  4. Givertz M, Colucci WS, Gottlieb SS, et al. Acute ET(A) receptor blockade reduces pulmonary vascular resistance in patients with chronic heart failure. Circulation 1998 Oct 27; 98 Suppl.: 578

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

TBC 11251. Drugs R&D 2, 38–39 (1999). https://doi.org/10.2165/00126839-199902010-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902010-00011

Keywords

Search

Navigation